- Home
- STTK vs TLSI Comparison
STTK vs TLSI Comparison
Compare STTK & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- TLSI
- Stock Information
- Founded
- STTK 2016
- TLSI 2010
- Country
- STTK United States
- TLSI United States
- Employees
- STTK N/A
- TLSI N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- TLSI Medical Specialities
- Sector
- STTK Health Care
- TLSI Health Care
- Exchange
- STTK Nasdaq
- TLSI Nasdaq
- Market Cap
- STTK 56.8M
- TLSI 124.9M
- IPO Year
- STTK 2020
- TLSI N/A
- Fundamental
- Price
- STTK $1.22
- TLSI $4.92
- Analyst Decision
- STTK Hold
- TLSI Strong Buy
- Analyst Count
- STTK 3
- TLSI 6
- Target Price
- STTK $2.00
- TLSI $11.75
- AVG Volume (30 Days)
- STTK 182.2K
- TLSI 36.4K
- Earning Date
- STTK 02-27-2025
- TLSI 11-14-2024
- Dividend Yield
- STTK N/A
- TLSI N/A
- EPS Growth
- STTK N/A
- TLSI N/A
- EPS
- STTK N/A
- TLSI N/A
- Revenue
- STTK $6,435,000.00
- TLSI $26,891,000.00
- Revenue This Year
- STTK $313.04
- TLSI $60.96
- Revenue Next Year
- STTK N/A
- TLSI $53.65
- P/E Ratio
- STTK N/A
- TLSI N/A
- Revenue Growth
- STTK 382.75
- TLSI 67.90
- 52 Week Low
- STTK $0.94
- TLSI $3.50
- 52 Week High
- STTK $11.76
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- STTK 43.75
- TLSI 51.68
- Support Level
- STTK $1.13
- TLSI $4.72
- Resistance Level
- STTK $1.39
- TLSI $5.32
- Average True Range (ATR)
- STTK 0.11
- TLSI 0.31
- MACD
- STTK 0.00
- TLSI 0.01
- Stochastic Oscillator
- STTK 18.18
- TLSI 47.52
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.